Be Vaccines Private Limited

Produces and sells human vaccines since 2012 in Telangana.

2012 | Hyderabad, Telangana (India) | Inactive
Last Updated: May 04, 2024

Be Vaccines Profile

Key Indicators

  • Authorised Capital ₹ 1.00 M
  • Paid Up Capital ₹ 0.10 M
  • Company Age 12 Year, 11 Months
  • Last Filing with ROC 31 Mar 2017
  • Revenue Growth %
  • Profit Growth -38.86%
  • Ebitda -1633.33%
  • Net Worth -12.33%
  • Total Assets -11.83%

About Be Vaccines

Be Vaccines Private Limited (BVPL) is Strike Off company established on 13 Mar 2012 with its office registered at Hyderabad, Telangana, India and has been running since 12 Year, 11 Months with a paid up capital of 0.10 M. According to MCA records, 2 Directors are linked to this company as of 04 May 2024.

Company Details

  • Location

    Hyderabad, Telangana, India

  • Telephone

    +91-XXXXXXXXXX

  • Email Address

  • Website

    -

  • Social Media
    -

Corporate Identity Details

  • CIN/LLPIN

    U24297TG2012PTC079725

  • Company No.

    079725

  • Company Classification

    Private Limited Indian Non-Government Company

  • Incorporation Date

    13 Mar 2012

  • Date of AGM

    29 Sep 2017

  • Date of Balance Sheet

    31 Mar 2017

  • Listing Status

    Unlisted

  • ROC Code

    Roc Hyderabad

Industry

Pharma

Who are the key members and board of directors at Be Vaccines?

Board Members (2)

NameDesignationAppointment DateStatus
Sridhar Raju Country flag representing In Additional Director 12-Apr-2013Current
Mahipal Saddi Country flag representing In Additional Director 28-Mar-2018Current

Financial Performance of Be Vaccines.

Be Vaccines Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 38.86% decrease in profit. The company's net worth observed a substantial decline by a decrease of 12.33%.

Graph illustrating revenue growth over time
Graph showing profit and loss trends over time
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023)YOY Growth
(FY 2022)(FY 2021)(FY 2020)(FY 2019)
Total Revenue
Revenue from Operations
Total Assets
-11.83%
Profit or Loss
-38.86%
Net Worth
-12.33%
EBITDA
-1633.33%

What is the Ownership and Shareholding Structure of Be Vaccines?

In 2017, Be Vaccines had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Shareholding Indicator graph

Charges (Loans)

Placeholder for charges-related data

There are no open charges registered against the company as per our records.

How Many Employees Work at Be Vaccines?

Unlock and access historical data on people associated with Be Vaccines, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.

Graph showing employee growth trends

Deals i

Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Be Vaccines, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Be Vaccines's trajectory.

Rating

Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts

Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Latest Updates, News, and FAQs on Be Vaccines

Recent activity within the organization

  • Director Appointment

    Mahipal Reddy Saddi was appointed as a Additional Director was appointed as a Additional Director on 28 Mar 2018 & has been associated with this company since 6 years 10 months .

    28 Mar 2018

  • Annual General Meeting

    Be Vaccines Private Limited last Annual general meeting of members was held on 29 Sep 2017 as per latest MCA records.

    29 Sep 2017

  • Balance Sheet

    Be Vaccines Private Limited has filed its annual Financial statements for the year ended 31 Mar 2017 with Roc Hyderabad.

    31 Mar 2017

  • Director Appointment

    Sridhar Pusapati Raju was appointed as a Additional Director was appointed as a Additional Director on 12 Apr 2013 & has been associated with this company since 11 years 10 months .

    12 Apr 2013

  • Company Incorporation

    Be Vaccines Private Limited was registered on 13 Mar 2012 with Roc Hyderabad & aged 12 years 11 months as per MCA records.

    13 Mar 2012

Frequently asked questions

  • Be Vaccines Private Limited was incorporated on 13 Mar 2012.

  • The authorized share capital of Be Vaccines Private Limited is ₹ 1.00 M and paid-up capital is ₹ 0.10 M.

  • Currently 2 directors are associated with Be Vaccines Private Limited.

    • Sridhar Pusapati Raju
    • Mahipal Reddy Saddi
  • As per Ministry of Corporate Affairs (Mca), the registered address of Be Vaccines Private Limited is 18/1 And 3, Azamabad, Hyderabad, Telangana, India, 500020.

  • The corporate identification number (CIN) of Be Vaccines Private Limited is U24297TG2012PTC079725 and the company number is 079725 as per Ministry of Corporate Affairs (MCA).

  • The financial reports for the fiscal year 2017 indicates that The net worth of Be Vaccines Private Limited has experienced an downturn of -12.33%.

  • The most recent Balance Sheet for Be Vaccines Private Limited was filed with the ROC on 31 Mar 2017.

People also Viewed

Similar Companies Based on Drug Formulation & Development